NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical- stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025. "Protara's inclusion in the Russell 3000 Index is a reflection of the progress that we have made executing acro ...